PTPN22 is a Potentially Diagnostic Biomarker for Abdominal Aortic Aneurysm

Abstract Background: Abdominal aortic aneurysm (AAA) is a severely life-threating disease; it is generally asymptomatic with diagnosis at a very late stage. Moreover, the genetic components and underpinnings in AAA is considerable with an estimated heritability of up to 70% roughly. Therefore, identifying the biomarkers for AAA is valuable toward predicting and eventually inspecting the high-risk populations. Methods: Herein, we used integrative bioinformatics and experimental analyses to reveal that protein tyrosine phosphatase non-receptor type 22 (PTPN22) can be a potentially diagnostic biomarker for AAA.Results: PTPN22, whose expression is significantly upregulated in aortic tissues of AAA, was primarily identified as a genetic biomarker for AAA, while it has no diagnostic value for patients with thoracic aortic aneurysm. Moreover, CaCl2-based in vitro AAA model was adopted to experimentally show that Garcinia acid could be a therapeutic drug for AAA. Conclusions: Collectively, these results indicate that PTPN22 may be a potentially diagnostic biomarker for AAA.